All Title Author
Keywords Abstract

PLOS ONE  2012 

Lack or Inhibition of Dopaminergic Stimulation Induces a Development Increase of Striatal Tyrosine Hydroxylase-Positive Interneurons

DOI: 10.1371/journal.pone.0044025

Full-Text   Cite this paper   Add to My Lib

Abstract:

We examined the role of endogenous dopamine (DA) in regulating the number of intrinsic tyrosine hydroxylase-positive (TH+) striatal neurons using mice at postnatal day (PND) 4 to 8, a period that corresponds to the developmental peak in the number of these neurons. We adopted the strategy of depleting endogenous DA by a 2-day treatment with α-methyl-p-tyrosine (αMpT, 150 mg/kg, i.p.). This treatment markedly increased the number of striatal TH+ neurons, assessed by stereological counting, and the increase was highly correlated to the extent of DA loss. Interestingly, TH+ neurons were found closer to the clusters of DA fibers after DA depletion, indicating that the concentration gradient of extracellular DA critically regulates the distribution of striatal TH+ neurons. A single i.p. injection of the D1 receptor antagonist, SCH23390 (0.1 mg/kg), the D2/D3 receptor antagonist, raclopride (0.1 mg/kg), or the D4 receptor antagonist, L-745,870 (5 mg/kg) in mice at PND4 also increased the number of TH+ neurons after 4 days. Treatment with the D1-like receptor agonist SKF38393 (10 mg/kg) or with the D2-like receptor agonist, quinpirole (1 mg/kg) did not change the number of TH+ neurons. At least the effects of SCH23390 were prevented by a combined treatment with SKF38393. Immunohistochemical analysis indicated that striatal TH+ neurons expressed D2 and D4 receptors, but not D1 receptors. Moreover, treatment with the α4β2 receptor antagonist dihydro-β-erythroidine (DHβE) (3.2 mg/kg) also increased the number of TH+ neurons. The evidence that DHβE mimicked the action of SCH23390 in increasing the number of TH+ neurons supports the hypothesis that activation of D1 receptors controls the number of striatal TH+ neurons by enhancing the release of acetylcholine. These data demonstrate for the first time that endogenous DA negatively regulates the number of striatal TH+ neurons by direct and indirect mechanisms mediated by multiple DA receptor subtypes.

References

[1]  Dubach M, Schmidt R, Kunkel D, Bowden DM, Martin R, et al. (1987) Primate neostriatal neurons containing tyrosine hydroxylase: immunohistochemical evidence. Neurosci Lett 75: 205–210.
[2]  Tashiro Y, Sugimoto T, Hattori T, Uemura Y, Nagatsu I, et al. (1989) Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat. Neurosci Lett 97: 6–10.
[3]  Betarbet R, Turner R, Chockkan V, DeLong MR, Allers KA, et al. (1997) Dopaminergic neurons intrinsic to the primate striatum. J Neurosci 17: 6761–6768.
[4]  Cossette M, Lévesque M, Parent A (1999) Extrastriatal dopaminergic innervation of human basal ganglia. Neurosci Res 34: 51–54.
[5]  Cossette M, Parent A, Lévesque D (2004) Tyrosine hydroxylase-positive neurons intrinsic to the human striatum express the transcription factor Nurr1. Eur J Neurosci 20: 2089–2095.
[6]  Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, et al. (2002) Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22: 4942–4954.
[7]  Lévesque M, Bédard A, Cossette M, Parent A (2003) Novel aspects of the chemical anatomy of the striatum and its efferents projections. J Chem Neuroanat 26: 271–281.
[8]  Huot P, Parent A (2007) Dopaminergic neurons intrinsic to the striatum. J Neurochem 101: 1441–1447.
[9]  Tandé D, Hoglinger G, Debeir T, Freundlieb N, Hirsch EC, et al. (2006) New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain 129: 1194–1200.
[10]  Meredith GE, Farrell T, Kellaghan P, Tan Y, Zahm DS, et al. (1999) Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions. Eur J Neurosci 11: 3585–3596.
[11]  Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, et al. (2000) New dopaminergic neurons in Parkinson's disease striatum. Lancet 356: 44–45.
[12]  Huot P, Lévesque M, Parent A (2007) The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 130: 222–232.
[13]  Spokes EG (1979) Dopamine in Huntington's disease: a study of postmortem brain tissue. Adv Neurol 23: 481–493.
[14]  Bird ED, Spokes EG, Iversen LL (1980) Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness. Acta Psychiatr Scand Suppl 280: 63–73.
[15]  Busceti CL, Biagioni F, Mastroiacovo F, Bucci D, Lenzi P, et al. (2008) High number of striatal dopaminergic neurons during early postnatal development: correlation analysis with dopaminergic fibers. J Neural Transm 115: 1375–1383.
[16]  Olson L, Seiger A, Fuxe K (1972) Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats. Brain Res 44: 283–288.
[17]  Tennyson VM, Barrett RE, Cohen G, Cotè L, Heikkila R, et al. (1972) The developing neostriatum of the rabbit: correlation of fluorescence histochemistry, electron microscopy, endogenous dopamine levels, and (3H)dopamine uptake. Brain Res 46: 251–285.
[18]  Caboche J, Rogard M, Besson MJ (1991) Comparative development of D1-dopamine and mu opiate receptors in normal and in 6-hydroxydopamine-lesioned neonatal rat striatum: dopaminergic fibers regulate mu but not D1 receptor distribution. Brain Res Dev Brain Res 58: 111–122.
[19]  Kreitzer AC (2009) Physiology and Pharmacology of Striatal Neurons. Annu Rev Neurosci 32: 127–147.
[20]  Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15: 133–139.
[21]  Masuda M, Miura M, Inoue R, Imanishi M, Saino-Saito S, et al. (2011) Postnatal development of tyrosine hydroxylase mRNA-expressing neurons in mouse neostriatum. Eur J Neurosci 2011 34: 1355–1367.
[22]  Restani P, Corsini E, Galimberti R, Galli CL (1990) Postnatal ontogenesis of dopaminergic and serotoninergic systems in rat caudate nucleus. Pharmacol Res 22: 343–350.
[23]  Andersen SL, Gazzara RA (1993) The ontogeny of apomorphine induced alterations of neostriatal dopamine release: effects on spontaneous release. J Neurochem 61: 2247–2255.
[24]  Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189–225.
[25]  Damsma G, Tham CS, Robertson GS, Fibiger HC (1990) Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat. Eur J Pharmacol 186: 335–338.
[26]  Aosaki T, Graybiel AM, Kimura M (1994) Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys. Science 265: 412–415.
[27]  Pisani A, Bonsi P, Centonze D, Calabresi P, Bernardi G (2000) Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J Neurosci 20: RC69.
[28]  Zhou FM, Liang Y, Dani JA (2001) Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4: 1224–1249.
[29]  Crawley JN, Hommer DW, Skirboll LR (1984) Behavioral and neurophysiological evidence for a facilatory interaction between co-existing transmitters: cholecystokinin and dopamine. Neurochem Int 6: 755–760.
[30]  Bédard A, Cossette M, Lévesque M, Parent A (2002) Proliferating cells can differentiate into neurons in the striatum of normal adult monkey. Neurosci Lett 328: 213–216.
[31]  Bédard A, Gravel C, Parent A (2006) Chemical characterization of newly generated neurons in the striatum of adult primates. Exp Brain Res 170: 501–512.
[32]  Tinti C, Conti B, Cubells JF, Kim KS, Baker H, et al. (1996) Inducible cAMP early repressor can modulate tyrosine hydroxylase gene expression after stimulation of cAMP synthesis. J Biol Chem 271: 25375–25381.
[33]  Tinti C, Yang C, Seo H, Conti B, Kim C, et al. (1997) Structure/function relationship of the cAMP response element in tyrosine hydroxylase gene transcription. J Biol Chem 272: 19158–19164.
[34]  Lim J, Yang C, Hong SJ, Kim KS (2000) Regulation of tyrosine hydroxylase gene transcription by the cAMP-signaling pathway: involvement of multiple transcription factors. Mol Cell Biochem 212: 51–60.
[35]  Kilbourne EJ, Osaka H, Sabban EL (1991) Hypomethylation of the rat tyrosine hydroxylase gene correlates with its expression in several cell types. Brain Res Dev Brain Res 58: 143–146.
[36]  Romano G, Macaluso M, Lucchetti C, Iacovitti L (2007) Transcription and epigenetic profile of the promoter, first exon and first intron of the human tyrosine hydroxylase gene. J Cell Physiol 211: 431–438.
[37]  Li J, Guo Y, Schroeder FA, Youngs RM, Schmidt TW, et al. (2004) Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem 90: 1117–1131.
[38]  Battaglia G, Busceti CL, Molinaro G, Biagioni F, Traficante F, et al. (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigro-striatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri?dine. J Neurosci 26: 7222–7229.
[39]  King MA, Scotty N, Klein RL, Meyer EM (2002) Particle detection, number estimation, and feature measurement in gene transfer studies: optical fractionator stereology integrated with digital image processing and analysis. Methods 28: 293–299.
[40]  Gundersen HJG, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229–263.

Full-Text

comments powered by Disqus